Navigation Links
New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
Date:10/15/2007

cylates (including mesalamine) or to any of the components of LIALDA. Caution should be exercised when treating patients with pyloric stenosis or those allergic to sulfasalazine. Mesalamine has been associated with an acute intolerance syndrome (three percent of patients in clinical trials with mesalamine or sulfasalazine) that may be difficult to distinguish from a flare of inflammatory bowel disease. If acute intolerance syndrome is suspected, prompt withdrawal is required. Mesalamine-induced cardiac hypersensitivity reactions (myocarditis and pericarditis) have been reported. Reports of renal impairment have been associated with mesalamine medications. In patients with renal impairment, caution should be exercised, and LIALDA should be used only if the benefits outweigh the risks. No information is available for patients with hepatic impairment.

LIALDA is generally well tolerated. The majority of adverse events in the double-blind, placebo-controlled trials were mild or moderate in severity. In clinical trials (n=535), the most common treatment-related adverse events with LIALDA 2.4g/day, 4.8g/day and placebo were headache (5.6 percent, 3.4 percent and 0.6 percent, respectively) and flatulence (4 percent, 2.8 percent and 2.8 percent, respectively). Pancreatitis occurred in less than 1 percent of patients during clinical trials and resulted in discontinuation of therapy with LIALDA.

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia
2. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
3. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Data Analyses Outline Efficacy and Safety of Mircera for the Treatment of Renal Anemia Associated With Chronic Kidney Disease
5. Safety Analyses of Clinical Data for Bifeprunox in Patients with Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar to Placebo
6. Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show
7. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
8. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
9. 8-Year Long-term Data Demonstrate Prolonged Overall Survival and Length of Disease Remission with Bexxar
10. Surfaxin (Lucinactant) Long-Term Survival Advantage vs. Comparators Published in Pediatrics
11. Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term Protection and Sterilizing Immunity in Nonhuman Primates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Therapeutics, Inc. (NASDAQ: SRNE ; Sorrento) today announced ... Officer and Executive Vice President. Mr. Singh died suddenly and ... "Sorrento is deeply saddened and shocked by the loss of ... Amar,s family and friends," said Henry Ji , Ph.D., ... Singh joined Sorrento in January 2014 from Synta Pharmaceuticals, where ...
(Date:7/31/2014)... July 31, 2014  ResMed Inc. (NYSE: RMD ... the fiscal year ended June 30, 2014.  Revenue for the ... June 30, 2013 (a 1 percent decrease on a constant ... 20 percent compared to the quarter ended June 30, 2013. ... increase of 22 percent compared to the quarter ended June ...
(Date:7/31/2014)... 2014 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... the quarter ended June 30, 2014. Financial Results ... Revenue Total revenue for the quarter ended June 30, ... quarter ended June 30, 2013 primarily due to IMBRUVICA ® ... Total revenue for the six months ended June 30, ...
Breaking Medicine Technology:Sorrento Announces the Unexpected Death of its Chief Business Officer 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23
... AT&T * today announced that the Arkansas Department ... mobile flu clinic solution to help the agency more efficiently ... to extend the use of the application to other year-round ... As an important part of its mission to ...
... 2011 Inhibitex, Inc. (Nasdaq: INHX ) today ... shares of its common stock, at a purchase price of ... The net proceeds to Inhibitex from the sale of the ... are expected to be approximately $44 million.  Inhibitex has granted ...
Cached Medicine Technology:Arkansas Department of Health Chooses AT&T to Streamline Delivery of Public Health Programs 2Arkansas Department of Health Chooses AT&T to Streamline Delivery of Public Health Programs 3Arkansas Department of Health Chooses AT&T to Streamline Delivery of Public Health Programs 4Inhibitex Prices $47 Million Public Offering 2Inhibitex Prices $47 Million Public Offering 3
(Date:8/2/2014)... (PRWEB) August 02, 2014 Apervi, ... orchestration platform simplifying data engineering for big data, ... is one of the first Enterprise data engineering ... Spark. Databricks, the company founded by the creators ... as a means to encourage new development on ...
(Date:8/2/2014)... (PRWEB) August 02, 2014 CEDR ... nation's number one provider of customized medical and dental ... major dental-industry conferences this fall. CEDR’s CEO will be ... September and early December. , From September 4-6, CEDR ... Office Managers (AADOM) Dental Managers Conference in San Diego, ...
(Date:8/1/2014)... Recently, iFitDress.com, one of the most famous dress suppliers ... top bridesmaid dresses online. At the moment, all the ... 52% off. According to the company’s senior spokesman, the special ... The company’s stock is limited. Those who are thinking of ... soon as possible. All its products are delicately made by ...
(Date:8/1/2014)... in St. Louis helps explain why brain tumors occur ... than similar tumors in females. For example, glioblastomas, the ... often in males, who suffer greater cognitive impairments than ... researchers found that retinoblastoma protein (RB), a protein known ... male brain cells than in female brain cells. , ...
(Date:8/1/2014)... 2014 Stryker hip lawsuits ( ... 2012 Rejuvenate and ABG II Modular-Neck Hip Stem ... Bergen County Superior Court, Bernstein Liebhard LLP reports. ... Court has issued a Final Amended Stipulated ... hard copy and electronic materials produced by any ...
Breaking Medicine News(10 mins):Health News:Databricks Certifies Apervi Conflux Director TM on Spark, Supercharging the Data to Insight Journey 2Health News:Databricks Certifies Apervi Conflux Director TM on Spark, Supercharging the Data to Insight Journey 3Health News:Nuanced Media Client, CEDR HR Solutions, to Speak at Upcoming Major Dental Conferences 2Health News:Nuanced Media Client, CEDR HR Solutions, to Speak at Upcoming Major Dental Conferences 3Health News:iFitDress.com: Top Bridesmaid Dresses For The Global Customers 2Health News:Study reveals one reason brain tumors are more common in men 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3
... inflammation and loss of cartilage in joints, is likely ... // ,Researchers led by David Felson, a professor ... with symptomatic osteoarthritis of the knee for 30 months. ... the online edition of BBC News. ,The ...
... for capacity Building', Ministry of Health and Family ... Rs. 1.50 crores or actual, whichever is less, ... State Hospitals of towns/cities located on National Highways. ... Road Transport and Highways and Ministry of Health ...
... an amazing figure at the cost of their own health. ... large population is opting for laxative abuse. ,Assumptions about ... which proved that 20% of women who wanted to lose ... students. ,Though these women start with few pills a ...
... 9th of November, urging parents to prevent use of fluoridated ... dentists are concerned about the exposure to fluoride at such ... teeth it might permanently damage them, apart from which it ... cancer boys. ,This advice is not noticed by many ...
... of food poison. Then, fame came as a temporary ... 'miracle poison' and used for an increasing number of ... Mayo Clinic Health Letter covers how this drug works ... ,Botulinum toxin blocks communication between nerves and muscles. Food ...
... the increasing number of children pronounced as juvenile diabetics, it ... such diseases //on their little ones. What used to ... silently attacking children, and it is imperative that parents and ... hand. ,New data from the International Diabetes ...
Cached Medicine News:Health News:Laxatives are Not the Right Option for Losing Weight 2
Stainless steel bone clamp....
Designed for proximal femoral elevation in total hip replacement or in other surgery with a similar need for bone manipulation....
To elevate, dissect, scrape and apply traction to bone and soft tissue....
The AV Plus DX pacing lead is designed for use with the St. Jude Medical Affinity VDR pulse generator. This single-lead pacing system provides reliable pacing therapy with the added benefits of AV sy...
Medicine Products: